Amedisys, Inc. AMED reported adjusted earnings per share (EPS) of $1.03 in the first quarter of 2024, which topped 3% from the year-ago quarter’s $1.00 per share. The bottom line also beat the Zacks Consensus Estimate by 1.9%. The quarter’s adjustments include certain merger-related expenses and other (income)/expenses, net. GAAP EPS in the first quarter was 59 cents compared to 23 cents in the same period last year. Net service revenues totaled $571.4 million, up 2.7% year over year. The top line surpassed the Zacks Consensus Estimate by 1.2%. Segments in Detail Net service revenues from the Home Health division totaled $364 million in the quarter, up 6% year over year. Within the segment, Medicare revenues of $215.8 million increased slightly by 0.2% year over year. Non-Medicare revenues improved by 15.9% year over year to $148.2 million. Within the Hospice division, net service revenues were $201 million (up 3.9% year over year), including Medicare revenues of $190 million (up 4%) and non-Medicare revenues of $11 million (up 2.8%). Amedisys, Inc. Price, Consensus and EPS Surprise Amedisys, Inc. Price, Consensus and EPS Surprise Amedisys, Inc. price-consensus-eps-surprise-chart | Amedisys, Inc. Quote Amedisys, Inc. Price, Consensus and EPS Surprise The High Acuity Care segment reported net service revenues of $6.4 million in the first quarter, which surged 36.2% from the year-ago quarter’s figure. The Corporate segment did not register any recognizable revenues in the first quarter. Margins The company's gross profit improved 3.5% to $249.9 million in the quarter under review. The gross margin expanded 35 basis points (bps) to 43.7%. Expenses on salaries and benefits rose 1.3% to $127.9 million. Other expenses fell 9.8% to $58 million. The adjusted operating profit amounted to $64 million, up 25.9% from the year-ago quarter’s levels. The adjusted operating margin expanded 207 bps to 11.2% from the prior-year quarter’s level. Liquidity and Cash Position Amedisys exited the first quarter with cash and cash equivalents of $108.2 million compared with $126.5 million at the end of 2023. The company's long-term obligations (excluding the current portion) were $356.1 million at the end of the first quarter of 2024 compared with $361.9 million at the end of 2023. Cumulative net cash used by operating activities at the end of the first quarter was $6.5 million compared with cash inflow of $26 million a year ago. Our Take Amedisys ended the first quarter of 2024 with better-than-expected earnings and revenues. The company’s impending merger with UnitedHealth Group’s Optum brings together two organizations dedicated to providing compassionate, value-based comprehensive care to patients and their families. Further, the expansion of both margins during the quarter is encouraging. Meanwhile, the uptick in Amedisys' operating income has been dampened by planned wage increases, wage inflation, a shift in the home health payor mix and investments in hospice clinical staffing. Zacks Rank and Other Key Picks Amedisys currently has a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Inspire Medical Systems INSP, Encompass Health EHC and HCA Healthcare HCA. Inspire Medical Systems, sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2023 EPS of 49 cents, which beat the Zacks Consensus Estimate of a loss of 4 cents. Revenues of $192.5 million topped the consensus estimate by 0.1%. You can see the complete list of today’s Zacks #1 Rank stocks here. Inspire Medical Systems has an estimated earnings growth rate of 51.4% in 2024 compared with the industry’s 20.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 353.6%. Encompass Health, carrying a Zacks Rank #2, reported a 2024 first-quarter EPS of $1.12, surpassing the Zacks Consensus Estimate by 20.4%. Revenues of $1.32 billion outpaced the Zacks Consensus Estimate by 3.6%. EHC has an estimated long-term earnings growth rate of 15% compared to the industry’s 11.7%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 18.7%. HCA Healthcare, carrying a Zacks Rank #2, reported a first-quarter 2024 EPS of $5.36, which surpassed the Zacks Consensus Estimate by 6.9%. Revenues of $17.3 billion topped the Zacks Consensus Estimate by 2.9%. HCA has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.9% growth. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 5.6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amedisys, Inc. (AMED):Free Stock Analysis Report HCA Healthcare, Inc. (HCA):Free Stock Analysis Report Encompass Health Corporation (EHC):Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...